Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes

Journal of Peptide Science : an Official Publication of the European Peptide Society
Rachna AnejaIrwin Chaiken

Abstract

Previously, we reported the discovery of macrocyclic peptide triazoles (cPTs) that bind to HIV-1 Env gp120, inhibit virus cell infection with nanomolar potencies, and cause irreversible virion inactivation. Given the appealing virus-killing activity of cPTs and resistance to protease cleavage observed in vitro, we here investigated in vivo pharmacokinetics of the cPT AAR029b. AAR029b was investigated both alone and encapsulated in a PEGylated liposome formulation that was designed to slowly release inhibitor. Pharmacokinetic analysis in rats showed that the half-life of FITC-AAR029b was substantial both alone and liposome-encapsulated, 2.92 and 8.87 hours, respectively. Importantly, liposome-encapsulated FITC-AAR029b exhibited a 15-fold reduced clearance rate from serum compared with the free FITC-cPT. This work thus demonstrated both the in vivo stability of cPT alone and the extent of pharmacokinetic enhancement via liposome encapsulation. The results obtained open the way to further develop cPTs as long-acting HIV-1 inactivators against HIV-1 infection.

References

Jul 2, 2003·Nature Medicine·Mario Stevenson
Aug 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Pin-Fang LinRichard Colonno
Feb 22, 2005·Methods in Enzymology·André Désormeaux, Michel G Bergeron
Apr 25, 2008·Current Protocols in Immunology·David C Montefiori
Aug 30, 2008·Methods in Molecular Biology·Håvard Jenssen, Stein Ivar Aspmo
Aug 3, 2010·ChemMedChem·Muddegowda UmashankaraIrwin Chaiken
Jun 30, 2011·ChemMedChem·Arangassery R BastianIrwin Chaiken
Jul 27, 2011·The Journal of Infectious Diseases·Susan SwindellsJeffrey M Jacobson
Nov 16, 2011·Antimicrobial Agents and Chemotherapy·Karyn McFaddenIrwin Chaiken
May 17, 2012·Viruses·Raveen ParboosingHendrik G Kruger
Oct 6, 2012·Advanced Drug Delivery Reviews·Theresa M Allen, Pieter R Cullis
Jan 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·Courtney V FletcherTimothy W Schacker
Jan 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·Surojit SurBert Vogelstein
Jun 4, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jennifer P Freeling, Rodney J Y Ho
Dec 17, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Lakshmi Narashimhan RamanaUma Maheswari Krishnan
May 21, 2015·Nature Immunology·Tae-Wook ChunAnthony S Fauci
Dec 10, 2015·Frontiers in Pharmacology·Lisa SercombeSusan Hua
Dec 30, 2015·Biochemistry·Ramalingam Venkat Kalyana SundaramIrwin M Chaiken
Oct 30, 2016·Current Opinion in Immunology·Jason T KimataJin Wang
Jul 28, 2016·Science·David M MargolisBarton F Haynes

❮ Previous
Next ❯

Citations

Aug 20, 2019·Current Topics in Medicinal Chemistry·Damoder Reddy MotatiE Blake Watkins
Sep 23, 2020·Archiv der Pharmazie·Lian-Shun FengDuan Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.